Should a 63-year-old male with Heart Failure with Reduced Ejection Fraction (HFrEF) (Diagnosed in 2023, Ejection Fraction 15-20%, Non-Ischemic Cardiomyopathy (NICM), Left Ventricular End-Diastolic Diameter (LVEDD) 7.4cm), history of Cerebrovascular Accident (CVA) (Right Middle Cerebral Artery (R-MCA), Left Hemiplegia, 2023), Chronic Kidney Disease (CKD) (Stage 3b), Hypertension (HTN), Hyperlipidemia (HLD), Right Lower Lobe (RLL) nodule, and malnutrition, who has undergone multiple hospitalizations for Acute Decompensated Heart Failure (ADHF) and is currently on Carvedilol (Beta Blocker) 3.125 mg twice daily, Jardiance (Empagliflozin) 10 mg daily, Valsartan (Angiotensin II Receptor Blocker) 20 mg twice daily, Spironolactone (Aldosterone Antagonist) 12.5 mg daily, and Atorvastatin (HMG-CoA Reductase Inhibitor) 80 mg daily, with significant Left Ventricular (LV) dysfunction, severe Mitral Regurgitation (MR), and unable to tolerate further Guideline-Directed Medical Therapy (GDMT) due to hypotension, be considered for a MitraClip procedure?
Last updated: April 9, 2025 • View editorial policy
Help us tailor your experience
Which best describes you? Your choice helps us use language that's most understandable for you.
Related Questions
Professional Medical Disclaimer
This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.
Have a follow-up question?
Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.